UBS Group
ABUS icon

UBS Group’s Arbutus Biopharma ABUS Stock Holding History

UBS Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-100
Closed -$2K – 8444
2015
Q1 		$2K Buy
+100
New +$2.05K ﹤0.01% 8420

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group's ABUS Position: Q2 2026 in Review

UBS Group reduced its Arbutus Biopharma (ABUS) stake by 32% in Q2 2026, selling an estimated $506K and leaving 249,208 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #5569.

UBS Group first reported a position in ABUS in Q4 2014 and has held it in 43 quarters since. The position peaked at $3.52M in Q3 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • UBS Group held 249,208 shares of Arbutus Biopharma worth $1.2M as of Q2 2026.
  • UBS Group sold 115,263 Arbutus Biopharma shares in Q2 2026, an estimated $506K.
  • Arbutus Biopharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5569 holding.
  • UBS Group first reported a position in Arbutus Biopharma in Q4 2014 and has held it in 43 quarters since.
  • UBS Group's Arbutus Biopharma position peaked at $3.52M in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.